Plasma cardiotrophin-1 levels are associated with hypertensive heart disease: a meta-analysis. - Wikidata - awgldk - TriplyDB

Plasma cardiotrophin-1 levels are associated with hypertensive heart disease: a meta-analysis.

Plasma cardiotrophin-1 levels are associated with hypertensive heart disease: a meta-analysis.

http://www.wikidata.org/entity/Q34156608

about

Potential novel biomarkers of cardiovascular dysfunction and disease: cardiotrophin-1, adipokines and galectin-3.The multi-biomarker approach for heart failure in patients with hypertension.Aging and the cardiac collagen matrix: Novel mediators of fibrotic remodelling Predictive Value for Galectin 3 and Cardiotrophin 1 in Hemodialysis Patients.

P2860

Q33897327-4DFBD142-4C98-4F67-892E-F9FD9A3232F6 Q35723466-E0709107-A2BF-47F8-96B5-B99F33F6E35D Q37096257-10DFDAEA-3713-48D0-8EA2-108F11DBFB6F Q40085529-FD620A53-7F84-437A-AB65-653DEC1081E5

P2860

Plasma cardiotrophin-1 levels are associated with hypertensive heart disease: a meta-analysis.

http://www.wikidata.org/entity/Q34156608

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Plasma cardiotrophin-1 levels ...... eart disease: a meta-analysis.

@ast

Plasma cardiotrophin-1 levels ...... eart disease: a meta-analysis.

@en

Plasma cardiotrophin-1 levels ...... eart disease: a meta-analysis.

@nl

type

label

Plasma cardiotrophin-1 levels ...... eart disease: a meta-analysis.

@ast

Plasma cardiotrophin-1 levels ...... eart disease: a meta-analysis.

@en

Plasma cardiotrophin-1 levels ...... eart disease: a meta-analysis.

@nl

prefLabel

Plasma cardiotrophin-1 levels ...... eart disease: a meta-analysis.

@ast

Plasma cardiotrophin-1 levels ...... eart disease: a meta-analysis.

@en

Plasma cardiotrophin-1 levels ...... eart disease: a meta-analysis.

@nl

P1433

Q34156608-C02A1295-AAA1-4CCD-86FE-3B9F017B35B9

P1476

Q34156608-0FF3EB84-E7CF-4F15-A2F7-30B381231F08

P2093

Q34156608-308169A9-610B-4FA4-BD30-B2C9BFC93D4E

Q34156608-50571A59-2799-4F53-8F7F-42763ED401BB

Q34156608-6F1825AB-67EF-4D38-95A1-9B40FF8ED389

Q34156608-F3AEAC05-2AED-49BF-BC82-E6D74D31F97A

P2860

Q34156608-0080F7C2-19DF-45F8-9867-2731BDAA468B

Q34156608-04FBB39F-11A7-491B-B64D-D8ABDC8CB5E2

Q34156608-06C574A1-F446-42EE-BDBE-0CACD580F2BC

Q34156608-0B3F97D2-6FC3-4FFC-B9E2-3E971BF76B20

Q34156608-254B3D88-AA5C-48B8-8533-8EA1A5406C47

Q34156608-358BBB1C-932A-4DE6-8E6B-97BBB2AFB575

Q34156608-3BA7C9C4-D5B6-43BE-A0C5-655D137616A0

Q34156608-4A8C725E-FCEC-41F9-9E48-407DDBFEBE90

Q34156608-4FD038ED-F4F8-4473-B378-618B099B5252

Q34156608-58319641-9C52-4A96-8001-C13F3EED97BA

P304

Q34156608-6C65A27D-74A7-4082-9B0B-5F911681D0E8

P31

Q34156608-2c1cfb24-329a-4bc2-976a-70495961905e

Q34156608-6DD3586B-85E2-4054-B262-336EDAB09D90

P356

Q34156608-96B13C82-52FD-471D-AE9F-79E1952701AE

P433

Q34156608-DC4020E2-D8F2-4D1A-81DB-029752BD5BBA

P478

Q34156608-DFC2ED37-8087-4A16-9566-A17E8015CC8E

P50

Q34156608-48EF2C93-EB16-4AEA-8D58-433B19E2C747

Q34156608-7DD298C9-387D-4C75-84AA-ECAD2DA228B0

P577

Q34156608-E432DB7E-4754-4C64-B5F8-A6B47053D285

P5875

Q34156608-947AC3E9-08C9-4530-8731-2681B0EF3BCA

P698

Q34156608-87DD5030-8C0F-4C21-9B10-3228186DFDCA

P932

Q34156608-E438A7FB-BB7A-4AA3-A594-207A05BDE6E2

P356

P1433

Journal of Clinical Hypertension

P1476

Plasma cardiotrophin-1 levels ...... heart disease: a meta-analysis

@en

P2093

Amelia Luciano

http://www.w3.org/2001/XMLSchema#string

Arya Mani

http://www.w3.org/2001/XMLSchema#string

Kangxing Song

http://www.w3.org/2001/XMLSchema#string

Shuxia Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Epidemiology and risk profile of heart failure

World Hypertension Day and global awareness

Measuring inconsistency in meta-analyses

Meta-analysis in clinical trials

Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the

Characterization of the protective effects of cardiotrophin-1 against non-ischemic death stimuli in adult cardiomyocytes

Cardiotrophin-1 and urocortin cause protection by the same pathway and hypertrophy via distinct pathways in cardiac myocytes

The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries.

Cardiotrophin-1 plasma levels are associated with the severity of hypertrophy in hypertrophic cardiomyopathy

P304

686-692

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/JCH.12376

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

Rakesh Srivastava

P577

2014-07-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

264162073

http://www.w3.org/2001/XMLSchema#string

P698

25052897

http://www.w3.org/2001/XMLSchema#string

P932

4159421

http://www.w3.org/2001/XMLSchema#string